Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabeth Piault

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
The Journal of Allergy and Clinical Immunology|July 14, 2010
The Childhood Asthma Control Test: retrospective determination and clinical validation of a cut point to identify children with very poorly controlled asthmaAndrew H Liu, Robert S Zeiger, Christine A Sorkness, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2020
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung CancerMartin Reck, Thomas Wehler, Francisco Orlandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2020
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab <b>+</b> Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell CarcinomaMichael B Atkins, Brian I Rini, Robert J Motzer, et al.
BJU International|April 2, 2020
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinomaSumanta K Pal, David F McDermott, Michael B Atkins, et al.
The Lancet. Oncology|September 8, 2018
Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic reviewMadeline Pe, Lien Dorme, Corneel Coens, et al.
Lancet (London, England)|May 14, 2019
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trialBrian I Rini, Thomas Powles, Michael B Atkins, et al.
Tropical Medicine and Health|November 7, 2025
A checklist for translating and adapting questionnaires (CTAQ) in healthcare research: insights from a Delphi method approachNguyen Tran Minh Duc, Kadek Agus Surya Dila, Duc Hoang Nguyen, et al.
Nature Medicine|October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Nature Medicine|June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
The Lancet. Oncology|February 3, 2020
International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL ConsortiumCorneel Coens, Madeline Pe, Amylou C Dueck, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
The Journal of Allergy and Clinical Immunology|July 14, 2010
The Childhood Asthma Control Test: retrospective determination and clinical validation of a cut point to identify children with very poorly controlled asthmaAndrew H Liu, Robert S Zeiger, Christine A Sorkness, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2020
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung CancerMartin Reck, Thomas Wehler, Francisco Orlandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2020
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab <b>+</b> Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell CarcinomaMichael B Atkins, Brian I Rini, Robert J Motzer, et al.
BJU International|April 2, 2020
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinomaSumanta K Pal, David F McDermott, Michael B Atkins, et al.
The Lancet. Oncology|September 8, 2018
Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic reviewMadeline Pe, Lien Dorme, Corneel Coens, et al.
Lancet (London, England)|May 14, 2019
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trialBrian I Rini, Thomas Powles, Michael B Atkins, et al.
Tropical Medicine and Health|November 7, 2025
A checklist for translating and adapting questionnaires (CTAQ) in healthcare research: insights from a Delphi method approachNguyen Tran Minh Duc, Kadek Agus Surya Dila, Duc Hoang Nguyen, et al.
Nature Medicine|October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Nature Medicine|June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
The Lancet. Oncology|February 3, 2020
International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL ConsortiumCorneel Coens, Madeline Pe, Amylou C Dueck, et al.
Pageof 3